Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW. Curtis JR, et al. Among authors: huizinga tw. Curr Med Res Opin. 2019 Sep;35(9):1483-1493. doi: 10.1080/03007995.2019.1585064. Epub 2019 Mar 14. Curr Med Res Opin. 2019. PMID: 30777458 Free article.
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Curtis JR, Weinblatt ME, Shadick NA, Brahe CH, Østergaard M, Hetland ML, Saevarsdottir S, Horton M, Mabey B, Flake DD 2nd, Ben-Shachar R, Sasso EH, Huizinga TW. Curtis JR, et al. Among authors: huizinga tw. Arthritis Res Ther. 2021 Jan 4;23(1):1. doi: 10.1186/s13075-020-02389-4. Arthritis Res Ther. 2021. PMID: 33397438 Free PMC article.
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. Quistrebert J, et al. Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12. Semin Arthritis Rheum. 2019. PMID: 30420245
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H. Behrens F, et al. Among authors: huizinga tw. Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17. Ann Rheum Dis. 2015. PMID: 24534756 Free PMC article. Clinical Trial.
Genetics in rheumatoid arthritis.
Huizinga TW. Huizinga TW. Curr Rheumatol Rep. 2002 Jun;4(3):195-200. doi: 10.1007/s11926-002-0065-2. Curr Rheumatol Rep. 2002. PMID: 12010603 Review.
Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge.
Plenge RM, Greenberg JD, Mangravite LM, Derry JM, Stahl EA, Coenen MJ, Barton A, Padyukov L, Klareskog L, Gregersen PK, Mariette X, Moreland LW, Bridges SL Jr, de Vries N, Huizinga TW, Guchelaar HJ; International Rheumatoid Arthritis Consortium (INTERACT); Friend SH, Stolovitzky G. Plenge RM, et al. Among authors: huizinga tw. Nat Genet. 2013 May;45(5):468-9. doi: 10.1038/ng.2623. Nat Genet. 2013. PMID: 23619782 Free PMC article. No abstract available.
927 results